These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 1107736)

  • 1. Gonadotropin releasing hormone (GnRH): neuropharmacological studies.
    Plotnikoff NP; White WF; Kastin AJ; Schally AV
    Life Sci; 1975 Dec; 17(11):1685-91. PubMed ID: 1107736
    [No Abstract]   [Full Text] [Related]  

  • 2. Neuropharmacological tests with alpha-melanocyte stimulating hormone.
    Plotnikoff NP; Kastin AJ
    Life Sci; 1976 Jun; 18(11):1217-22. PubMed ID: 933712
    [No Abstract]   [Full Text] [Related]  

  • 3. Growth hormone release inhibiting hormone: neuropharmacological studies.
    Plotnikoff NP; Kastin AJ; Schally AV
    Pharmacol Biochem Behav; 1974; 2(5):693-6. PubMed ID: 4610595
    [No Abstract]   [Full Text] [Related]  

  • 4. Study of the structural requirements for dopa potentiation and oxotremorine antagonism by L-prolyl-L-leucylglycinamide.
    Johnson RL; Smissman EE; Plotnikoff NP
    J Med Chem; 1978 Feb; 21(2):165-9. PubMed ID: 23433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropharmacological review of hypothalamic releasing factors.
    Plotnikoff NP; Kastin AJ
    Adv Biochem Psychopharmacol; 1977; 17():81-107. PubMed ID: 411333
    [No Abstract]   [Full Text] [Related]  

  • 6. Neuropharmacological actions of enkephalin after systemic administration.
    Plotnikoff NP; Kastin AJ; Coy DH; Christensen CW; Schally AV; Spirtes MA
    Life Sci; 1976 Oct; 19(8):1283-8. PubMed ID: 186682
    [No Abstract]   [Full Text] [Related]  

  • 7. TRH potentiates behavioural changes following increased brain 5-hydroxytryptamine accumulation in rats.
    Green AR; Grahame-Smith DG
    Nature; 1974 Oct; 251(5475):524-6. PubMed ID: 4214262
    [No Abstract]   [Full Text] [Related]  

  • 8. Thyrotropin releasing hormone: enhancement of dopa activity by a hypothalamic hormone.
    Plotnikoff NP; Prange AJ; Breese GR; Anderson MS; Wilson IC
    Science; 1972 Oct; 178(4059):417-8. PubMed ID: 4627781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A study of the central effects of 5,6-dihydroxytryptamine.
    Longo VG; Scotti de Carolis A; Liuzzi A; Massotti M
    Adv Biochem Psychopharmacol; 1974; 10():109-20. PubMed ID: 4546514
    [No Abstract]   [Full Text] [Related]  

  • 10. Potentiation by amantadine hydrochloride of L-dopa-induced effects in mice.
    Svensson TH; Strömberg U
    J Pharm Pharmacol; 1970 Aug; 22(8):639-40. PubMed ID: 4394549
    [No Abstract]   [Full Text] [Related]  

  • 11. Behavior and biochemical effects of preferentially protecting monoamines in the brain against the action of reserpine.
    Butcher LL; Rhodes DL; Yuwiler A
    Eur J Pharmacol; 1972 May; 18(2):204-12. PubMed ID: 4537669
    [No Abstract]   [Full Text] [Related]  

  • 12. Behavioral, biochemical, and histochemical analyses of the central effects of monoamine precursors after peripheral decarboxylase inhibition.
    Butcher LL; Engel J; Fuxe K
    Brain Res; 1972 Jun; 41(2):387-411. PubMed ID: 4402607
    [No Abstract]   [Full Text] [Related]  

  • 13. [Activity of toloxatone, antidepressive agents and various other reserpine antagonists on three behavior tests, in the mouse treated with nialamide].
    Gouret C; Raynaud G
    Therapie; 1975; 30(2):225-30. PubMed ID: 1080583
    [No Abstract]   [Full Text] [Related]  

  • 14. Gonadotropin-releasing hormone agonist blocks anxiogenic-like and depressant-like effect of corticotrophin-releasing hormone in mice.
    Umathe SN; Bhutada PS; Jain NS; Shukla NR; Mundhada YR; Dixit PV
    Neuropeptides; 2008 Aug; 42(4):399-410. PubMed ID: 18533256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the uptake of noradrenaline and 5-hydroxytryptamine by chlorphentermine and chlorimipramine.
    Ross SB; Renyi AL; Ogren SO
    Eur J Pharmacol; 1972 Jan; 17(1):107-12. PubMed ID: 4536952
    [No Abstract]   [Full Text] [Related]  

  • 16. Oxotremorine antagonism by prolyl-leucyl-glycine-amide administered by different routes and with several anticholinergics.
    Plotnikoff NP; Kastin AJ
    Pharmacol Biochem Behav; 1974 May; 2(3):417-9. PubMed ID: 4837910
    [No Abstract]   [Full Text] [Related]  

  • 17. Analysis of aggressiveness-stereotype complex induced in mice by amphetamine or nialamide and L-dopa.
    Roliński Z
    Pol J Pharmacol Pharm; 1973; 25(6):551-8. PubMed ID: 4799834
    [No Abstract]   [Full Text] [Related]  

  • 18. Prolyl-leucyl-glycine amide (PLG) and thyrotropin-releasing hormone (TRH): DOPA potentiation and biogenic amine studies.
    Plotnikoff NP
    Prog Brain Res; 1975; 42():11-23. PubMed ID: 730
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects on general behaviour and neurotransmitter functions of a new 5-hydroxytryptamine3 receptor antagonist with potential therapeutic relevance in central nervous system disturbances.
    Rizzi CA; Prudentino A; Giraldo E
    Arzneimittelforschung; 1993 Oct; 43(10):1033-41. PubMed ID: 7903536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of serotonin in the pathophysiology of myoclonic seizures associated with acute imipramine toxicity.
    Westheimer R; Klawans HL
    Neurology; 1974 Dec; 24(12):1175-7. PubMed ID: 4548513
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.